dehydroabietylamine has been researched along with abietic acid in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aicher, TD; Brand, LJ; Damon, RE; Gao, J; Kaplan, EL; Koletar, J; Mann, WR; Shetty, SS; Vinluan, CC | 1 |
| Connelly, M; Fatima, I; Gautam, LN; González, MA; Ling, T; Miranda-Carboni, G; Rivas, F; Tran, M; Wood, RK | 1 |
| Gowda, DC; Gowda, R; Inamdar, GS; Kuzu, OF; Rangappa, KS; Robertson, GP; Sadashiva, MP; Wu, X | 1 |
3 other study(ies) available for dehydroabietylamine and abietic acid
| Article | Year |
|---|---|
Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Diterpenes; Mice; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Triterpenes | 1999 |
(+)-Dehydroabietylamine derivatives target triple-negative breast cancer.
Topics: Abietanes; Antineoplastic Agents, Phytogenic; Apoptosis; Biological Products; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; Humans; MCF-7 Cells; Molecular Structure; Stereoisomerism; Structure-Activity Relationship; Triple Negative Breast Neoplasms | 2015 |
A non-cytotoxic N-dehydroabietylamine derivative with potent antimalarial activity.
Topics: Abietanes; Antimalarials; Benzamides; Benzothiazoles; Cell Line; Cell Line, Tumor; Diamines; Dose-Response Relationship, Drug; Erythrocytes; Fibroblasts; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Organic Chemicals; Plasmodium falciparum; Quinolines; Structure-Activity Relationship | 2015 |